[Rosiglitazone (BRL-49653)].
Oka
Yoshitomo
Y
Division of Molecular Metabolism and Diabetes, Department of Internal Medicine, Tohoku University Graduate School of Medicine.
D000818:Animals; D050260:Carbohydrate Metabolism; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007333:Insulin Resistance; D050356:Lipid Metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000502:physiology; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077154:Rosiglitazone